earnings
confidence high
sentiment positive
materiality 0.85
Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint
Natera, Inc.
2025-Q3 EPS reported
-$1.88
revenue$1,640,615,000
- Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.
- Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.
- Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.
- Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.
- FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M.